Bersavin: Nový bisbenzylisochinolinový alkaloid s cytotoxickými, antiproliferativními a apoptózovými účinky na lidské leukemické buňky

Bersavine is the new bisbenzylisoquinoline alkaloid isolated from the Berberis vulgaris L. (Berberidaceae) plant. The results of cytotoxicity screening 48 h post-treatment showed that bersavine considerably inhibits the proliferation and viability of leukemic (Jurkat, MOLT-4), colon (HT-29), cervix (HeLa) and breast (MCF-7) cancer cells with IC50 values ranging from 8.1 to 11 mu M. The viability and proliferation of leukemic Jurkat and MOLT-4 cells were decreased after bersavine treatment in a time- and dose-dependent manner. Bersavine manifested concentration-dependent antiproliferative activity in human lung, breast, ovarian and hepatocellular carcinoma cell lines using a xCELLigence assay. Significantly higher percentages of MOLT-4 cells exposed to bersavine at 20 mu M for 24 h were arrested in the G1 phase of the cell cycle using the flow cytometry method. The higher percentage of apoptotic cells was measured after 24 h of bersavine treatment. The upregulation of p53 phosphorylated on Ser392 was detected during the progression of MOLT-4 cell apoptosis. Mechanistically, bersavine-induced apoptosis is an effect of increased activity of caspases, while reduced proliferation seems dependent on increased Chk1 Ser345 phosphorylation and decreased Rb Ser807/811 phosphorylation in human leukemic cells.Bersavin je nový bisbenzylisochinolinový alkaloid izolovaný z rostliny Berberis vulgaris L. (Berberidaceae). Výsledky cytotoxického screeningu po 48 hodinách ukázaly, že bersavin významně inhibuje proliferaci a životaschopnost leukemických (Jurkat, MOLT-4), tlustého střeva (HT-29), děložního čípku (HeLa) a karcinomu prsu (MCF-7) s hodnotami IC50 v rozmezí od 8,1 do 11 uM. Viabilita a proliferace leukemických buněk Jurkat a MOLT-4 byla po ovlivnění bersavinem snížena v závislosti na čase a dávce. Bersavin vykazoval na koncentraci závislou antiproliferativní aktivitu u lidských nádorových linií plic, prsu, vaječníků a hepatocelulárního karcinomu pomocí testu xCELLigence. Významně vyšší procento buněk MOLT-4 ovlivněných bersavinem v dávce 20 uM po dobu 24 hodin bylo zastaveno ve fázi G1 buněčného cyklu měřeného pomocí průtokové cytometrie. Vyšší procento apoptotických buněk bylo zjištěno za 24 hodin po ovlivnění bersavinem. Zvýšená exprese p53 fosforylovaného na Ser392 byla detekována během progrese apoptózy u buněk MOLT-4. Apoptóza indukovaná bersavinem je důsledkem zvýšené aktivity kaspáz, zatímco, snížená proliferace závisí pravděpodobně na zvýšené fosforylaci Chk1 Ser345 a snížené fosforylaci Rb Ser807 / 811 u lidských leukemických buněk

Protinádorový potenciál alkaloidů čeledi Amaryllidaceae testovaný na panelu lidských linií, pomocí analýzy buněk v reálném čase a na Ehrlichově nádoru myší

In this study, twenty-two Amaryllidaceae alkaloids were screened for their anticancer potential. All isolates were evaluated for antiproliferative activities on a panel of 17 human cell types of different tissue origin using WST-1 assay. In addition, we determined the antiproliferative effect with a real-time cell analysis xCELLigence system. Thereafter, to evaluate the barely known in vivo anticancer potential of the most potent molecule haemanthamine, a preliminary study was performed using an Ehrlich tumor-bearing mice model. The results showed that haemanthamine, lycorine and haemanthidine exerted the highest antiproliferative activity. The mean growth percent (GP) value after a single-dose 10 mu M treatment was for haemanthamine 21%, for lycorine 21% and for haemanthidine 27% that of untreated control cells (100%). Furthermore, haemanthamine, lycorine and haemanthidine exhibited significant cytotoxicities against all the tested cell lines with individual IC50 values in the micromolar range. Dynamic real-time measures of impedance by xCELLigence indicated that these three compounds suppress cell proliferation after 10 h of treatment at a concentration of 10 mM or higher. Regrettably, in a follow-up in vivo antitumor activity study, haemanthamine showed no statistically significant reduction in the tumor size with no prolongation of survival time of Ehrlich tumor-bearing mice. Taken together, these results provide a new clue and guidance for exploiting Amaryllidaceae alkaloids as anticancer agents.V této studii byl testován protinádorový potenciál 22 alkaloidů čeledi Amaryllidaceae na panelu lidských linií, pomocí analýzy buněk v reálném čase a na Ehrlichově nádoru myší

In vitro a in silico stanovení inhibiční aktivity thaliktrikavinu a kanadinu vůči acetylcholinesteráze a odhad jejich přestupu přes hematoencefalickou bariéru

In recent studies, several alkaloids acting as cholinesterase inhibitors were isolated from Corydalis cava (Papaveraceae). Inhibitory activities of (+)-thalictricavine (1) and (+)-canadine (2) on human acetylcholinesterase (hAChE) and butyrylcholinesterase (hBChE) were evaluated with the Ellman's spectrophotometric method. Molecular modeling was used to inspect the binding mode of compounds into the active site pocket of hAChE. The possible permeability of 1 and 2 through the blood-brain barrier (BBB) was predicted by the parallel artificial permeation assay (PAMPA) and logBB calculation. In vitro, 1 and 2 were found to be selective hAChE inhibitors with IC50 values of 0.38 +/- 0.05 mu M and 0.70 +/- 0.07 mu M, respectively, but against hBChE were considered inactive (IC50 values > 100 mu M). Furthermore, both alkaloids demonstrated a competitive-type pattern of hAChE inhibition and bind, most probably, in the same AChE sub-site as its substrate. In silico docking experiments allowed us to confirm their binding poses into the active center of hAChE. Based on the PAMPA and logBB calculation, 2 is potentially centrally active, but for 1 BBB crossing is limited. In conclusion, 1 and 2 appear as potential lead compounds for the treatment of Alzheimer's disease.Z Corydalis cava (Papaveraceae) bylo izolováno několik alkaloidů půsbících jako inhibitory cholinesterázy. Inhibiční aktivity (+) - thaliktrikavinu (1) a (+) - kanadinu (2) na lidskou acetylcholinesterázu (hAChE) a butyrylcholinesterázu (hBChE) byly hodnoceny pomocí Ellmanovy spektrofotometrické metody. K ověření způsobu vazby testovaných sloučenin do aktivního místa hAChE bylo použito molekulové modelování. Možná permeabilita 1 a 2 hematoencefalickou bariérou (HEB) ​​byla předpovězena pomocí testu paralelní umělé permeace (PAMPA) a logBB. In vitro bylo zjištěno, že 1 a 2 jsou selektivní inhibitory hAChE s hodnotami IC50 0,38 +/- 0,05 uM, respektive 0,70 +/- 0,07 uM, ale při inhibici hBChE byly považovány za neaktivní (hodnoty IC50> 100 uM). Oba alkaloidy prokázaly kompetitivní typ inhibice hAChE a vážou se s největší pravděpodobností na stejném AChE sub-místě jako jeho substrát. In silico dokovací experimenty potvrdily vazebné pozice v aktivním místě AChE. Na základě výpočtu PAMPA a logBB je 2 potenciálně centrálně aktivní, ale pro 1 je přechod HEB omezen

Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment

AKR1B10 is an NADPH-dependent reductase that plays an important function in several physiological reactions such as the conversion of retinal to retinol, reduction of isoprenyl aldehydes, and biotransformation of procarcinogens and drugs. A growing body of evidence points to the important role of the enzyme in the development of several types of cancer (e.g., breast, hepatocellular), in which it is highly overexpressed. AKR1B10 is regarded as a therapeutic target for the treatment of these diseases, and potent and specific inhibitors may be promising therapeutic agents. Several inhibitors of AKR1B10 have been described, but the area of natural plant products has been investigated sparingly. In the present study almost 40 diverse phenolic compounds and alkaloids were examined for their ability to inhibit the recombinant AKR1B10 enzyme. The most potent inhibitorsapigenin, luteolin, and 7-hydroxyflavonewere further characterized in terms of IC₅₀, selectivity, and mode of action. Molecular docking studies were also conducted, which identified putative binding residues important for the interaction. In addition, cellular studies demonstrated a significant inhibition of the AKR1B10-mediated reduction of daunorubicin in intact cells by these inhibitors without a considerable cytotoxic effect. Although these compounds are moderately potent and selective inhibitors of AKR1B10, they constitute a new structural type of AKR1B10 inhibitor and may serve as a template for the development of better inhibitors